Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REVIVAL study of carboplatin + olaparib followed by olaparib versus capecitabine in BRCA-mutated HER2-negative advanced breast cancer
NL-OMON46924Phase 2Active, not recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- May 2015
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of olaparib, carboplatin and capecitabine in breast cancer (3 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Recommended phase II dose. Started May 2015; status: active, not recruiting.
02
Drugs
olaparibcarboplatincapecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON46924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46924.